Form 4: DiaMedica Therapeutics Director Charles Pauling Semba Acquires Shares Via Restricted Stock Units

Director Charles Pauling Semba acquired 5,290 shares of DiaMedica Therapeutics through a restricted stock unit award in lieu of cash retainer fees.

Summary

• On January 2, 2025, Charles Pauling Semba, a director of DiaMedica Therapeutics Inc., acquired 5,290 shares of the company's voting common stock.
• The acquisition was made through a restricted stock unit (RSU) award, granted under the company's 2019 Omnibus Incentive Plan, in lieu of $28,250 in cash retainer fees.
• The price per share was $5.34.
• The RSU award will vest in four nearly equal installments on March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025.
• Following the transaction, Semba directly owns 44,608 shares, which includes the 5,290 shares issuable on vesting of the RSU award.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, but the amount is relatively small and part of a standard compensation package.

Positives

• Director's acquisition of shares demonstrates confidence in the company.
• The use of RSUs in lieu of cash retainer fees conserves company cash.

Industry Context

Director share acquisitions are common and can be seen as a positive signal, indicating confidence in the company's future prospects. Using equity in lieu of cash compensation is a common practice to preserve cash, especially for companies in the biotechnology sector.

Comparison to Industry Standards

• Comparing this transaction to similar transactions in the biotech industry, directors often receive equity compensation as part of their overall remuneration.
• The size of the RSU award ($28,250 in lieu of cash) is relatively small, suggesting it's a standard component of director compensation.
• Other biotech companies like Amgen or Gilead Sciences also use equity-based compensation for their board members.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment.
• Employees may view the director's share acquisition as a sign of confidence in the company's future.

Key Dates